• Home
• Products
  • UV Phototherapy
  • Derma 308
  • MED/MPD Tester
• Order
• FAQ
  • UV Phototherapy
  • Viedo
  • Instruction
  • Real stories
• Membership
• Contact
•  
• KERNEL
  • KERNEL Website
  • Colposcope
  • Photodynamic therapy
  • Patient monitor

Sequential combined therapy with thalidomide and narrow-band (TL01) UVB in the treatment of prurigo nodularis.

BACKGROUND:

Prurigo nodularis (PN) is a chronic disease of which treatment choices are limited. Among them, thalidomide and 

phototherapy have been used with satisfactory results. Unfortunately, the possibility of side effects limits their 

use.

OBJECTIVE:

To evaluate the efficacy of a sequential combined treatment with thalidomide and ultraviolet B (UVB) therapy in order 

to minimize side effects and, thus, making possible a long-term treatment.

METHODS:

A prospective open trial combining thalidomide as initial therapy followed by narrow-band UVB (TL01) irradiation until 

complete or almost complete remission of the disease was achieved.

RESULTS:

An excellent response was obtained after an average of 12 weeks of thalidomide therapy and 32 UVB courses.

CONCLUSIONS:

Sequential combined therapy with thalidomide and narrow-band UVB therapy could improve the management of prurigo 

nodularis with minimal side effects, although it should probably be reserved to men and women over 50 years of age.

www.kerneluvb.com----The leader manufacturer of UVB Phototherapy.